NL1033520A1 - Ghrelinebindende nucleïnezuren. - Google Patents

Ghrelinebindende nucleïnezuren.

Info

Publication number
NL1033520A1
NL1033520A1 NL1033520A NL1033520A NL1033520A1 NL 1033520 A1 NL1033520 A1 NL 1033520A1 NL 1033520 A NL1033520 A NL 1033520A NL 1033520 A NL1033520 A NL 1033520A NL 1033520 A1 NL1033520 A1 NL 1033520A1
Authority
NL
Netherlands
Prior art keywords
nucleic acids
binding nucleic
ghrelin binding
ghrelin
acids
Prior art date
Application number
NL1033520A
Other languages
English (en)
Other versions
NL1033520C2 (nl
Inventor
Florian Jarosch
Dirk Eulberg
Christian Maasch
Steffen Helmling
Sven Klussmann
Original Assignee
Noxxon Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noxxon Pharma Ag filed Critical Noxxon Pharma Ag
Publication of NL1033520A1 publication Critical patent/NL1033520A1/nl
Application granted granted Critical
Publication of NL1033520C2 publication Critical patent/NL1033520C2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormones [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3183—Diol linkers, e.g. glycols or propanediols
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
NL1033520A 2005-04-08 2007-03-08 Ghrelinebindende nucleïnezuren. NL1033520C2 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05007795 2005-04-08
EP05007795 2005-04-08

Publications (2)

Publication Number Publication Date
NL1033520A1 true NL1033520A1 (nl) 2007-08-06
NL1033520C2 NL1033520C2 (nl) 2010-01-21

Family

ID=37087373

Family Applications (2)

Application Number Title Priority Date Filing Date
NL1031538A NL1031538C2 (nl) 2005-04-08 2006-04-07 Ghrelinebindende nucleïnezuren.
NL1033520A NL1033520C2 (nl) 2005-04-08 2007-03-08 Ghrelinebindende nucleïnezuren.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NL1031538A NL1031538C2 (nl) 2005-04-08 2006-04-07 Ghrelinebindende nucleïnezuren.

Country Status (24)

Country Link
US (2) US8101734B2 (nl)
EP (1) EP1866412A2 (nl)
JP (2) JP5308813B2 (nl)
KR (1) KR20080009072A (nl)
CN (1) CN101189337B (nl)
AP (1) AP2007004189A0 (nl)
AR (1) AR052741A1 (nl)
AU (1) AU2006233647A1 (nl)
BR (1) BRPI0608180A2 (nl)
CA (1) CA2605377A1 (nl)
CR (1) CR9423A (nl)
DO (1) DOP2006000085A (nl)
EA (1) EA200701901A1 (nl)
GB (1) GB2439673A (nl)
GT (1) GT200600137A (nl)
IL (1) IL186085A0 (nl)
MA (1) MA29384B1 (nl)
MX (1) MX2007012419A (nl)
NL (2) NL1031538C2 (nl)
PE (1) PE20061358A1 (nl)
TN (1) TNSN07375A1 (nl)
TW (1) TW200718781A (nl)
UY (1) UY29460A1 (nl)
WO (1) WO2006108599A2 (nl)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003251681A1 (en) * 2002-08-01 2004-02-23 Noxxon Pharma Ag Ghrelin binding nucleic acids
EA009376B1 (ru) * 2003-11-10 2007-12-28 Нокссон Фарма Аг Нуклеиновые кислоты, специфично связывающие биоактивный грелин
AR052741A1 (es) 2005-04-08 2007-03-28 Noxxon Pharma Ag Acidos nucleicos de union a ghrelin
EP2274331B1 (en) 2008-05-02 2013-11-06 Novartis AG Improved fibronectin-based binding molecules and uses thereof
US8796216B2 (en) * 2008-06-12 2014-08-05 Syntaxin Limited Suppression of neuroendocrine diseases
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
US8951966B2 (en) 2011-07-01 2015-02-10 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases
EP3798228A1 (en) 2012-11-28 2021-03-31 NGM Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
CN108888757A (zh) 2012-12-27 2018-11-27 恩格姆生物制药公司 用于调节胆汁酸体内稳态及治疗胆汁酸紊乱和疾病的方法
EP2986306A4 (en) 2013-04-18 2016-12-07 Armo Biosciences Inc METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
CA2914837A1 (en) 2013-06-17 2014-12-24 Armo Biosciences, Inc. Method for assessing protein identity and stability
EP3038642A4 (en) 2013-08-30 2017-01-18 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
JP6660297B2 (ja) 2013-11-11 2020-03-11 アルモ・バイオサイエンシーズ・インコーポレイテッド 疾患及び障害を処置するためのインターロイキン−１０の使用方法
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
WO2015095811A2 (en) 2013-12-20 2015-06-25 The Board Institute Inc. Combination therapy with neoantigen vaccine
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
WO2016060996A2 (en) 2014-10-14 2016-04-21 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
JP6675394B2 (ja) 2014-10-22 2020-04-01 アルモ・バイオサイエンシーズ・インコーポレイテッド 疾患及び障害の治療のためにインターロイキン−１０を使用する方法
KR102569907B1 (ko) 2014-10-23 2023-08-24 엔지엠 바이오파마슈티컬스, 아이엔씨. 펩티드 변이체를 포함하는 약제학적 조성물 및 그의 사용 방법
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
WO2016100977A1 (en) 2014-12-19 2016-06-23 The Broad Institute Inc. Methods for profiling the t-cel- receptor repertoire
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
MX2017014700A (es) 2015-05-20 2018-08-15 Broad Inst Inc Neoantigenos compartidos.
AU2016268403A1 (en) 2015-05-28 2017-12-07 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
EP3341012A4 (en) 2015-08-25 2019-03-20 Armo Biosciences, Inc. METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
EP3377090B1 (en) 2015-11-09 2021-04-07 NGM Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
WO2017184590A1 (en) 2016-04-18 2017-10-26 The Broad Institute Inc. Improved hla epitope prediction
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
KR20230119735A (ko) 2017-02-12 2023-08-16 바이오엔테크 유에스 인크. Hla 기반 방법 및 조성물, 및 이들의 용도
WO2019094268A1 (en) 2017-11-10 2019-05-16 Armo Biosciences, Inc. Compositions and methods of use of interleukin-10 in combination with immune checkpoint pathway inhibitors
TW201930340A (zh) 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途
CN112533629A (zh) 2018-06-19 2021-03-19 阿尔莫生物科技股份有限公司 结合使用il-10药剂与嵌合抗原受体细胞疗法的组合物和方法
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
MX2021007556A (es) 2018-12-21 2021-09-10 Biontech Us Inc Método y sistemas de predicción de epítopos específicos de hla de clase ii y caracterización de células t cd4+.
JPWO2020250923A1 (nl) * 2019-06-11 2020-12-17
KR20230142704A (ko) 2020-12-14 2023-10-11 바이오엔테크 유에스 인크. 암 면역요법을 위한 조직 특이적 항원
WO2024077256A1 (en) 2022-10-07 2024-04-11 The General Hospital Corporation Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614395A (en) 1988-03-08 1997-03-25 Ciba-Geigy Corporation Chemically regulatable and anti-pathogenic DNA sequences and uses thereof
CA2084987C (en) 1990-06-11 2007-02-13 Larry Gold Nucleic acid ligands
US6232071B1 (en) * 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
WO1996034879A1 (en) 1995-05-03 1996-11-07 Whitehead Institute For Biomedical Research Identification of enantiomeric ligands
DE19808591C2 (de) 1998-02-28 2000-02-03 Univ Leipzig Standardisierter durchflußzytometrischer Vollblutassay
AU2001259056A1 (en) 2000-05-17 2001-11-26 Eli Lilly And Company Method for selectively inhibiting ghrelin action
US20030211967A1 (en) 2001-05-07 2003-11-13 Bryant Henry Uhlman Method for selectively inhibiting ghrelin action
JP2004514651A (ja) 2000-05-30 2004-05-20 メルク　エンド　カムパニー　インコーポレーテッド グレリン類似体
DK2431377T3 (en) * 2001-10-26 2017-08-14 Noxxon Pharma Ag Modified L-nucleic acids
AU2003251681A1 (en) * 2002-08-01 2004-02-23 Noxxon Pharma Ag Ghrelin binding nucleic acids
EA009376B1 (ru) 2003-11-10 2007-12-28 Нокссон Фарма Аг Нуклеиновые кислоты, специфично связывающие биоактивный грелин
AR052741A1 (es) 2005-04-08 2007-03-28 Noxxon Pharma Ag Acidos nucleicos de union a ghrelin

Also Published As

Publication number Publication date
GB2439673A (en) 2008-01-02
TW200718781A (en) 2007-05-16
TNSN07375A1 (fr) 2009-03-17
PE20061358A1 (es) 2007-01-13
GT200600137A (es) 2006-11-22
NL1033520C2 (nl) 2010-01-21
GB0719489D0 (en) 2007-11-21
US20120115937A1 (en) 2012-05-10
US20060258607A1 (en) 2006-11-16
JP2008534024A (ja) 2008-08-28
KR20080009072A (ko) 2008-01-24
US8101734B2 (en) 2012-01-24
EP1866412A2 (en) 2007-12-19
JP2013176372A (ja) 2013-09-09
IL186085A0 (en) 2008-01-20
BRPI0608180A2 (pt) 2009-11-17
AU2006233647A2 (en) 2008-04-17
NL1031538C2 (nl) 2007-03-20
CN101189337A (zh) 2008-05-28
NL1031538A1 (nl) 2006-10-10
EA200701901A1 (ru) 2008-04-28
AP2007004189A0 (en) 2007-10-31
WO2006108599A3 (en) 2007-02-15
JP5308813B2 (ja) 2013-10-09
CA2605377A1 (en) 2006-10-19
DOP2006000085A (es) 2006-11-15
AU2006233647A1 (en) 2006-10-19
CR9423A (es) 2007-12-17
CN101189337B (zh) 2013-11-06
MX2007012419A (es) 2007-12-05
AR052741A1 (es) 2007-03-28
WO2006108599A2 (en) 2006-10-19
UY29460A1 (es) 2006-11-30
MA29384B1 (fr) 2008-04-01

Similar Documents

Publication Publication Date Title
NL1031538A1 (nl) Ghrelinebindende nucleïnezuren.
CY2020009I1 (el) Δεσμευτικοι παραγοντες σκληροστινης
NL300935I2 (nl) guselkumab.
NL1028967A1 (nl) 4-Fenylamino-chinazoline-6-yl-amiden.
NO20051199L (no) Rorhandteringsutstyr.
NO20052535D0 (no) Polynucleotide.
NO20041374D0 (no) Bolgekraftverk.
NO20053362L (no) Syklofuge.
NO20040762D0 (no) Stromskinne.
ITVE20050008U1 (it) Elemento riscaldante.
NL1028622A1 (nl) Stelwig.
FI20050547A0 (fi) Side
ES1056663Y (es) Abrazadera.
ITRM20050027A1 (it) Munizione.
NL1025196A1 (nl) Hark-Zeef-Vork.
FI20050927A0 (fi) Sidontalaite
FI20050718A0 (fi) Sidontalaite
FI20050349A0 (fi) Sidontalaite
FI20050009A0 (fi) Sidontalaite
ES1057576Y (es) Grapa centrador.
NO20053098D0 (no) Forbedret limsystem.
ES1060050Y (es) Palillo pinza.
FI20041026A0 (fi) Sidontalaite
FI20041350A0 (fi) Sidontalaite
ITPZ20040011U1 (it) Eco-power a1.

Legal Events

Date Code Title Description
AD1A A request for search or an international type search has been filed
PD2A A request for search or an international type search has been filed
V1 Lapsed because of non-payment of the annual fee

Effective date: 20101101